Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer

Abstract KRAS oncoprotein is commonly mutated in human cancer, but effective therapies specifically targeting KRAS‐driven tumors remain elusive. Here, we show that combined treatment with fibroblast growth factor receptor 1 (FGFR1) and polo‐like kinase 1 (PLK1) inhibitors evoke synergistic cytotoxic...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhang Yang, Shun‐Qing Liang, Maria Saliakoura, Haitang Yang, Eric Vassella, Georgia Konstantinidou, Mario Tschan, Balazs Hegedüs, Liang Zhao, Yanyun Gao, Duo Xu, Haibin Deng, Thomas M Marti, Gregor J Kocher, Wenxiang Wang, Ralph A Schmid, Ren‐Wang Peng
Format: Article
Language:English
Published: Springer Nature 2021-08-01
Series:EMBO Molecular Medicine
Subjects:
autophagy
fibroblast growth factor receptor 1
KRAS‐mutant cancer
polo‐like kinase 1
synthetic lethal vulnerability
Online Access:https://doi.org/10.15252/emmm.202013193
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/emmm.202013193

Similar Items